How can the immune response affect the effectiveness of VTP?

The immune response can significantly affect the effectiveness of Vascular Targeted Photodynamic (VTP) therapy, particularly in relation to its ability to enhance anti-tumor immunity. A systemic immune response initiated by the VTP process can lead to the recognition and destruction of residual cancer cells that may remain post-treatment. This phenomenon is especially important as it can contribute to reducing the chances of cancer recurrence.

The VTP approach not only focuses on the direct photodynamic effects on the tumor but also leverages the body's immune system to mount a response against tumor antigens that become more prominent after the initial treatment. This dual action can potentially improve long-term outcomes for patients undergoing VTP by enabling the immune system to "remember" and target any returning cancer cells, thereby aiding in the overall fight against cancer.